Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14638747 | 0.80 | NPSR1 (0.38) | — | |
| SCHEMBL10073174 | 0.76 | ALDH1A1 (0.33) | SMN1; SMN2 | |
| SCHEMBL10072896 | 0.74 | — | — | |
| SCHEMBL24796109 | 0.72 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL2728634 | 0.72 | CYP2C19 (0.32) | — | |
| SCHEMBL19231488 | 0.71 | — | — | |
| SCHEMBL21738681 | 0.70 | — | — | |
| SCHEMBL18653337 | 0.70 | — | — | |
| SCHEMBL23366120 | 0.70 | — | — | |
| SCHEMBL18087338 | 0.67 | CYP2C19 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3922269-A1 | EXTENDED RELEASE CONJUGATES OF EXENATIDE ANALOGS | Prolynx LLC (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20200164083-A1 | EXTENDED RELEASE CONJUGATES OF EXENATIDE ANALOGS | PROLYNX LLC (US) | 2020-05-28 | — | — | US | disclosed |
| US-10413594-B2 | Conjugates of somatostatin analogues | PROLYNX LLC (US) | 2019-09-17 | — | — | US | disclosed |
| CN-109414469-A | The sustained release conjugate of Exenatide analog | 普罗林科斯有限责任公司 | 2019-03-01 | — | — | CN | disclosed |
| EP-3429608-A1 | EXTENDED RELEASE CONJUGATES OF EXENATIDE ANALOGS | Prolynx LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| US-20180296648-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | PROLYNX LLC (US) | 2018-10-18 | — | — | US | disclosed |
| US-10086049-B2 | Conjugates of somatostatin analogues | PROLYNX LLC (US) | 2018-10-02 | — | — | US | disclosed |
| WO-2017161174-A1 | EXTENDED RELEASE CONJUGATES OF EXENATIDE ANALOGS | PROLYNX LLC (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | PROLYNX LLC (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3060230-A1 | CONJUGATES OF SOMATOSTATIN AND ITS ANALOGS | Prolynx LLC (US) | 2016-08-31 | — | — | EP | disclosed |
| WO-2015061503-A1 | CONJUGATES OF SOMATOSTATIN AND ITS ANALOGS | PROLYNX LLC (US) | 2015-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200164083-A1 | EXTENDED RELEASE CONJUGATES OF EXENATIDE ANALOGS | GLP1R, IAPP, GIPR | SMN1; SMN2 213/4885 |
| US-20180296648-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | SSTR4, SSTR3, SSTR2 | SMN1; SMN2 993/4885 |
| US-20160271227-A1 | CONJUGATES OF SOMATOSTATIN ANALOGUES | SSTR4, SSTR3, SSTR2 | SMN1; SMN2 993/4885 |
| US-10413594-B2 | Conjugates of somatostatin analogues | SSTR4, SSTR3, SSTR2 | SMN1; SMN2 993/4885 |
| US-10086049-B2 | Conjugates of somatostatin analogues | SSTR4, SSTR3, SSTR2 | SMN1; SMN2 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.